Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Probiodrug AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Probiodrug AG, Medical Devices Deals, 2012 to YTD 2018 10
Probiodrug AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Probiodrug AG, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Probiodrug Secures US$19.5 Million In Series C Financing 12
Partnerships 14
Probiodrug to Enter into Agreement with Julius Clinical 14
Probiodrug Enters into Research Agreement with Paul-Flechsig-Institute 15
Probiodrug Enters Into Co-Development Agreement With VU University Medical Center 16
Evotec Enters Into Co-Development Agreement With Probiodrug For Glutaminyl Cyclase 17
Licensing Agreements 18
Probiodrug Extends Licensing Agreement with Crossbeta Biosciences 18
QPS Austria Enters into Licensing Agreement with Probiodrug 19
Equity Offering 20
Probiodrug Raises USD17.8 Million in Private Placement of Shares 20
Probiodrug Raises USD14.7 Million in Private Placement of Shares 22
Probiodrug Completes IPO for USD29.6 Million 23
Asset Transactions 25
AstraZeneca Acquires CDK9 Inhibitor Program From Probiodrug 25
Probiodrug AG – Key Competitors 27
Probiodrug AG – Key Employees 28
Probiodrug AG – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
May 15, 2018: Probiodrug reports First Quarter 2018 Business Update 30
Apr 03, 2018: Probiodrug reports full year 2017 financial results 34
Nov 30, 2017: Probiodrug reports Third Quarter 2017 Business Update 39
Aug 31, 2017: Probiodrug reports financial results for H1 2017 and corporate update 43
May 12, 2017: Probiodrug reports First Quarter 2017 Business Update 47
Mar 30, 2017: Probiodrug reports full year 2016 financial results 49
Corporate Communications 53
Oct 05, 2018: Probiodrug Reports Management Changes 53
Product News 54
05/16/2017: Probiodrug Announces Acceptance of PQ912 Pharmacology Paper by Peer Reviewed Journal 54
04/23/2018: Probiodrug Appoints Dr. Ulrich Dauer as Chief Executive Officer 55
03/28/2017: Probiodrug To Present At Alzheimers And Parkinsons Diseases Congress 56
03/16/2018: Probiodrug to Present at 255th ACS National Meeting & Exposition 57
Clinical Trials 58
Oct 26, 2017: Probiodrug to Present Data from its Phase 2a SAPHIR Study at International Alzheimer’s Disease Conference 58
Oct 16, 2017: Probiodrug initiates Phase 2b core program of PQ912 and details further strategy 59
Jun 11, 2017: Probiodrug announces encouraging results of the Phase 2a SAPHIR Study 60
Apr 10, 2017: Probiodrug to present at Huntington’s Disease Therapeutics Conference 62
Apr 07, 2017: Probiodrug Last Patient Last Visit reached in the SAPHIR Study 63
Jan 09, 2017: Probiodrug announces completion of recruitment for the SAPHIR Phase 2a study of Glutaminyl Cyclase Inhibitor PQ912 in early Alzheimer’s disease patients 64
Other Significant Developments 65
Aug 30, 2018: Probiodrug announces financial results for H1 2018 65
Appendix 67
Methodology 67
About GlobalData 67
Contact Us 67
Disclaimer 67
Probiodrug AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Probiodrug AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Probiodrug AG, Deals By Therapy Area, 2012 to YTD 2018 9
Probiodrug AG, Medical Devices Deals, 2012 to YTD 2018 10
Probiodrug AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Probiodrug Secures US$19.5 Million In Series C Financing 12
Probiodrug to Enter into Agreement with Julius Clinical 14
Probiodrug Enters into Research Agreement with Paul-Flechsig-Institute 15
Probiodrug Enters Into Co-Development Agreement With VU University Medical Center 16
Evotec Enters Into Co-Development Agreement With Probiodrug For Glutaminyl Cyclase 17
Probiodrug Extends Licensing Agreement with Crossbeta Biosciences 18
QPS Austria Enters into Licensing Agreement with Probiodrug 19
Probiodrug Raises USD17.8 Million in Private Placement of Shares 20
Probiodrug Raises USD14.7 Million in Private Placement of Shares 22
Probiodrug Completes IPO for USD29.6 Million 23
AstraZeneca Acquires CDK9 Inhibitor Program From Probiodrug 25
Probiodrug AG, Key Competitors 27
Probiodrug AG, Key Employees 28
Probiodrug AG, Subsidiaries 29
List of Figures
Probiodrug AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Probiodrug AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Probiodrug AG, Medical Devices Deals, 2012 to YTD 2018 10
【免責事項】
http://www.globalresearch.jp/disclaimer